Kynurenine pathway abnormalities in Parkinson's disease

Neurology

Volumn 42, Issue 9, 1992, Pages 1702-1706

  Ogawa, Tatsuji ^a,e   Matson, W R ^b   Beal, M F ^c   Myers, R H ^d   Bird, E D ^a   Milbury, P ^b   Saso, S ^e  

^a MCLEAN HOSPITAL   (United States)

^b ESA Inc   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON UNIVERSITY   (United States)

^e MIYAGI NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; KYNURENIC ACID; KYNURENINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TRYPTOPHAN; TYROSINE;

ARTICLE; BRAIN MITOCHONDRION; BRAIN TISSUE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; HUMAN; HUMAN TISSUE; MITOCHONDRIAL RESPIRATION; NEUROCHEMISTRY; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SEROTONIN BRAIN LEVEL; SUBSTANTIA NIGRA; TRYPTOPHAN METABOLISM;

AGED; AUTOPSY; BRAIN; FEMALE; HUMAN; KYNURENINE; MALE; PARKINSON DISEASE; TRYPTOPHAN; TYROSINE;

EID: 0026671306     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.42.9.1702     Document Type: Article

References (28)

1. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
2. Nagatsu T, Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 1988;87:178-182.
3. Caine DB, Eisen A, McGeer E, Spencer P. Alzheimer’s disease, Parkinson’s disease, and motoneurone disease: abiotropic interaction between aging and environment? Lancet 1986;2:1067-1070.
4. Ramsay RR, Singer TP. Energy dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxie metabolite of 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine by mitochondria. J Biol Chem 1986;261:7585-7587.
5. Parker WD, Boyson SJ, Parks JK. Electron transport chain abnormalities in idiopathic Parkinson’s disease. Ann Neurol 1989;26:719-723.
6. Schapira AHV, Dexter D, Cooper JM, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 1990;54:823-827.
7. Wolfensberger M, Amsler U, Cuenod M, Foster AC, Whetsell WO Jr, Schwarcz R. Identification of quinolinic acid in rat and human brain tissue. Neurosci Lett 1983;41:247-252.
8. Moroni F, Lombardi G, Moneti G, Aldinio C. The excitotoxin quinolinic acid is present in the brain of several mammals and its cortical content increases during the aging process. Neurosci Lett 1984;47:51-55.
9. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983;219:316-318.
10. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 1986;321:168-171.
11. Ganong AH, Lanthorn TH, Cotman CW. Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord. Brain Res 1983;273:170-174.
12. Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 1984;48:273-278.
13. Beninger RJ, Jhamandas K, Boegman RJ, El-Defrawy S. Kynurenic acid-induced protection of neurochemical and behavioral deficits produced by quinolinic acid injections into the nucleus basalis of rats. Neurosci Lett 1986;68:317-321.
14. Stone TW, Connick JH. Quinolinic acid and other kynurenines in the central nervous system. Neuroscience 1985;15:597-617.
15. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Kynurenine pathway measurements in Huntington’s disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 1990;55:1327-1339.
16. Matson WR, Langlais P, Volicer L, Gamache PH, Bird E, Mark KA. n-Electrode three-dimensional liquid chromatography with electrochemical detection for determination of neurotransmitters. Clin Chem 1984;30:1477-1488.
17. Matson WR, Gamache PG, Beal MF, Bird ED. EC array sensor concepts and data. Life Sci 1987;41:905-908.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
19. Rinne UK, Sonninen V, Hyyppa M. Effect of L-dopa on brain monoamines and their metabolites in Parkinson’s disease. Life Sci 1971;10:549-557.
20. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res 1983;275:321-328.
21. Sharpless NS, McCann DS. Dopa and 3-O-methyldopa in cerebrospinal fluid of parkinsonism patients during treatment with oral L-dopa. Clin Chim Acta 1971;31:155-169.
22. Kuruma I, Bartholini G, Pletscher A. L-Dopa-induced accumulation of 3-O-methyldopa in brain and heart. Eur J Pharmacol 1970;10:189-192.
23. Kuruma I, Bartholini G, Tissot R, Pletscher A. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 1971;12:678-682.
24. Swartz KJ, During MJ, Freese A, Beal MF. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990;10:2965-2973.
25. Guilarte TR, Wagner HN. Increased concentrations of 3-hydroxykynurenine in vitamin B6 deficient neonatal rat brain. J Neurochem 1987;49:1918-1926.
26. Bloem BR, Irwin I, Buruma OJS, et al. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson’s disease. J Neurol Sci 1990;97:273-293.
27. Turski L, Bressler K, Rettig K-J, Loschmann PA, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by IV-methyl-D-aspartate antagonists. Nature 1991;349:414-418.
28. Storey E, Hyman BT, Jenkins B, et al. l-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 1992;58:1975-1978.